Literature DB >> 21281557

Acute nicotine enhances strategy-based semantic processing in Parkinson's disease.

Anna D Holmes1, David A Copland, Peter A Silburn, Helen J Chenery.   

Abstract

Nicotinic mechanisms may play a role in the cognitive deficits of Parkinson's disease (PD). Recently, on a cognitively demanding strategy-based priming task, nicotine selectively affected controlled semantic processing in young adult non-smokers as reported by Holmes et al. (International Journal of Neuropsychopharmacology 11, 389-399, 2008). Such controlled semantic processing is compromised in PD. This study investigated the effects of acute transdermal nicotine on controlled semantic processing in non-smokers with PD (n = 10) and non-smoking matched controls (n = 16) using a strategy-based semantic priming paradigm. Transdermal nicotine patches (7 mg/24 h) were administered in a double-blind, placebo-controlled, crossover design. Participants were instructed to expect target words from specified semantic categories based on the primes, while unexpected targets were also presented. Priming conditions included those concurring with trained expectations (expected-related and expected-unrelated), those which did not (unexpected-related and unexpected-unrelated), and neutral-baseline conditions. Controls evidenced significant expectancy effects (i.e. reaction-time differences for expected vs. unexpected conditions) under both drug states. An expectancy effect was not evident for PD under placebo due to a lack of reaction-time slowing for unexpected conditions. However, under nicotine an expectancy effect was present for PD at a level comparable to controls. Overall the findings indicate that nicotine can improve impaired controlled semantic processing in PD possibly via enhanced expectancy or inhibitory mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281557     DOI: 10.1017/S1461145710001665

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  8 in total

1.  Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.

Authors:  D Aarsland; C Ballard; A Rongve; M Broadstock; P Svenningsson
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 2.  Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease.

Authors:  Xiomara A Perez
Journal:  Neuropsychol Rev       Date:  2015-11-09       Impact factor: 7.444

3.  The two-way relationship between nicotine and cortical activity: a systematic review of neurobiological and treatment aspects.

Authors:  Carlota de Miquel; Benjamin Pross; Irina Papazova; Duygu Güler; Alkomiet Hasan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-06-27       Impact factor: 5.270

4.  Nicotinic receptors in neurodegeneration.

Authors:  Inmaculada Posadas; Beatriz López-Hernández; Valentín Ceña
Journal:  Curr Neuropharmacol       Date:  2013-05       Impact factor: 7.363

5.  The promise of neuroprotective agents in Parkinson's disease.

Authors:  Stacey E Seidl; Judith A Potashkin
Journal:  Front Neurol       Date:  2011-11-21       Impact factor: 4.003

Review 6.  Pharmacological enhancement of memory or cognition in normal subjects.

Authors:  Gary Lynch; Conor D Cox; Christine M Gall
Journal:  Front Syst Neurosci       Date:  2014-05-20

Review 7.  Boosting visual cortex function and plasticity with acetylcholine to enhance visual perception.

Authors:  Jun Il Kang; Frédéric Huppé-Gourgues; Elvire Vaucher
Journal:  Front Syst Neurosci       Date:  2014-09-18

Review 8.  Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.

Authors:  Wen-Yu Hsu; Hsien-Yuan Lane; Chieh-Hsin Lin
Journal:  Front Psychiatry       Date:  2018-04-04       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.